2 results
Approved WMOCompleted
Primary objectiveTo assess the efficacy of LYS006 versus placebo on facial inflammatory lesion counts in patients with moderate to severe inflammatory acneSecondary objectiveTo assess the safety and tolerability of LYS006 in patients with moderate…
Approved WMORecruiting
Primary Part 1:-To evaluate ORR in participants treated with MK-4280A plus EV (Arm A), MK-7684A plus EV (Arm B), and pembrolizumab plus EV(Arm C) per RECIST 1.1 by BICR.- To evaluate the safety and tolerability in participants treated with MK-4280A…